Clinical Trials Logo

Clinical Trial Summary

RATIONALE: AMG 706 and octreotide may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth and by blocking blood flow to the tumor. PURPOSE: This phase II trial is studying how well AMG 706 and octreotide work in treating patients with low-grade neuroendocrine tumors.


Clinical Trial Description

OBJECTIVES: Primary - Determine the 4-month progression-free survival (PFS) of patients with low-grade neuroendocrine tumors treated with AMG 706 and octreotide acetate. Secondary - Determine the response rate and overall survival of patients treated with these drugs. - Determine the toxicity and tolerability of AMG 706 in these patients. - Determine the effect of AMG 706 on tumor perfusion by functional computerized tomography (CT) scan. - Determine the effect of AMG 706 on tumor markers (e.g., chromogranin A, 5-hydroxyindoleacetic acid, and gastrin) specific for neuroendocrine tumors. - Determine the effect of AMG 706 on serum vascular endothelial growth factor (VEGF) levels. - Determine the expression of VEGF, VEGF receptor-2 (VEGFR-2), chromogranin A, human achaete-scute homolog-1 (hASH1), and Notch1 markers of neuroendocrine tumors. OUTLINE: This is a multicenter study. Patients receive oral AMG 706 and octreotide acetate intramuscularly once daily on days 1-28. Treatment repeats every 28 days in the absence of disease progression or unacceptable toxicity. Plasma samples are collected at baseline, periodically during study treatment, and at 4 weeks after the completion of study treatment. Samples are used to determine plasma VEGF levels. Gene expression of downstream markers of Raf kinase expression (raf, MEK, and ERK) as well as hASH1 and Notch1 are evaluated at baseline. Tumor tissue collected at diagnosis or prior surgery is examined by reverse transcriptase-polymerase chain reaction assay. Contrast CT scans are conducted at baseline, day 2 of course 1, and week 8 to assess tumor perfusion. After the completion of study treatment, patients are followed periodically for 5 years. PROJECTED ACCRUAL: A total of 44 patients will be accrued for this study. ;


Study Design


Related Conditions & MeSH terms


NCT number NCT00427349
Study type Interventional
Source Eastern Cooperative Oncology Group
Contact
Status Completed
Phase Phase 2
Start date November 7, 2008
Completion date April 2015

See also
  Status Clinical Trial Phase
Completed NCT01048892 - Seneca Valley Virus-001 and Cyclophosphamide in Treating Young Patients With Relapsed or Refractory Neuroblastoma, Rhabdomyosarcoma, or Rare Tumors With Neuroendocrine Features Phase 1
Terminated NCT00903396 - Palonosetron Hydrochloride in Preventing Nausea and Vomiting Caused by Radiation Therapy in Patients With Primary Abdominal Cancer Phase 2
Active, not recruiting NCT00436735 - Nelfinavir in Treating Patients With Metastatic, Refractory, or Recurrent Solid Tumors Phase 1
Completed NCT00002470 - Fluorouracil Plus Interferon Alfa in Treating Patients With Advanced Metastatic Carcinoid Tumors Phase 2
Active, not recruiting NCT00454376 - Disease-Specific Questionnaire in Assessing Quality of Life in Patients With Gastrointestinal-Related Neuroendocrine Tumors Phase 4
Terminated NCT00002947 - Indium In 111 Pentetreotide in Treating Patients With Refractory Cancer Phase 1
Completed NCT00416767 - Combination Chemotherapy as First-Line Therapy in Treating Patients With Locally Advanced or Metastatic Neuroendocrine Tumors of the Duodenum or Pancreas That Cannot Be Removed By Surgery Phase 2
Completed NCT00005049 - Combination Chemotherapy in Treating Patients With Stage III Ovarian Epithelial Cancer or Gastrointestinal Cancer Phase 2
Completed NCT00027638 - Thalidomide in Treating Patients With Metastatic Neuroendocrine Tumors Phase 2
Completed NCT00019474 - Combination Chemotherapy Plus Interferon Alfa Followed by Filgrastim in Treating Patients With Gastrointestinal Tract Cancer Phase 2
Terminated NCT00227617 - Combination Chemotherapy and Bevacizumab in Treating Patients With Advanced Neuroendocrine Tumors Phase 2/Phase 3
Completed NCT00654160 - Irinotecan, Fluorouracil, and Leucovorin in Treating Patients With Advanced Gastrointestinal Cancer Phase 1
Completed NCT00049023 - Radiolabeled Octreotide in Treating Children With Advanced or Refractory Solid Tumors Phase 1
Completed NCT00004911 - Endoscopic Placement of Metal Stent in Patients With Cancer-Related Bowel Obstruction Phase 1/Phase 2
Completed NCT00004910 - Endoscopic Placement of Metal Stents in Treating Patients With Cancer- Related Duodenal Obstruction Phase 1/Phase 2
Completed NCT00006368 - Yttrium Y 90 SMT 487 in Treating Patients With Refractory or Recurrent Cancer Phase 1
Active, not recruiting NCT00730483 - Doxorubicin Beads in Treating Patients With Unresectable Liver Metastases From Neuroendocrine Tumors N/A
Completed NCT00602082 - Capecitabine and Streptozocin With or Without Cisplatin in Treating Patients With Unresectable or Metastatic Neuroendocrine Tumors Phase 2
Completed NCT00017199 - PS-341 in Treating Patients With Metastatic Neuroendocrine Tumors Phase 2
Completed NCT00003427 - Oxaliplatin Plus Irinotecan in Treating Patients With Metastatic Gastrointestinal Cancer Phase 1